Apollo Invests in vVARDIS Dental Tech, Reaching $1B Valuation

Global investment firm Apollo has injected significant capital into vVARDIS, a Swiss innovator in dental medicine technology. This strategic minority investment propels the company past the $1 billion valuation mark, establishing it as a prominent privately held healthcare unicorn within Europe. The infusion of funds is earmarked to accelerate vVARDIS's commercial expansion, particularly in the crucial United States and European markets.

At the heart of vVARDIS's growth strategy is its pioneering Curodont product line. These non-invasive, peptide-based formulations represent a paradigm shift in treating early-stage tooth decay, offering a drill-free alternative that has demonstrated clinical efficacy. The technology's impact is already substantial; since its introduction in the U.S. just over two years ago, Curodont has been utilized in the treatment of approximately three million teeth. Its adoption is widespread, now reaching nearly 20% of general dental practices across the nation.

The backing from Apollo underscores the firm's keen interest in high-growth healthcare ventures possessing robust clinical validation. The dental sector, particularly in restorative treatments, presents a vast opportunity. In the U.S. alone, the addressable market for tooth decay solutions exceeds $30 billion, with nearly 90% of the adult population affected by this condition. vVARDIS is strategically positioned to capture a significant share of this market with its innovative approach.

Drs. Haley and Goly Abivardi, the founders and co-chief executive officers of vVARDIS, will continue to lead the company, retaining a substantial majority ownership. Their vision for a less invasive approach to dental care has been the driving force behind the company's success. The partnership with Apollo, which manages approximately $938 billion in assets as of year-end 2025, provides not only financial resources but also strategic expertise to navigate global market expansion.

Jeremy Honeth, Partner at Apollo, and Andrea Vanni, Managing Director, highlighted vVARDIS's achievement in building a distinct business supported by rigorous peer-reviewed research. They emphasized that this investment will facilitate the broader rollout of their restorative therapy, making it accessible to a greater number of dental professionals and patients worldwide. This move aligns with the broader trend of increased investment in healthtech solutions that offer improved patient outcomes and operational efficiencies for healthcare providers.

The valuation achieved by vVARDIS places it among a select group of European healthtech companies that have reached unicorn status. This milestone reflects the growing investor confidence in innovative medical technologies that address significant unmet needs. The company's focus on preventative and minimally invasive treatments resonates with evolving patient preferences and healthcare system priorities, suggesting a strong trajectory for future growth and market penetration.